 In order to test this hypothesis we will study stable patients on optimal drug therapy with documented cardiomyopathy using a trial design where therapy will be randomized, double-blinded and placebo-controlled. This will reduce the likelihood of any researcher bias. Patients will be recruited from the Heart-failure Service at the Royal Brompton Hospital. 